Current partner codePEPTIDESDE
NCT00938717·Phase 3·INTERVENTIONAL

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status

Completed

Phase

Phase 3

Enrollment

805

Locations

107

Results

Posted

Publications

2

Study summary

What the protocol is testing.

The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).

Interventions

Treatment arms and agents.

DRUG

Linaclotide or Matching Placebo

Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial

Timeline

From registration to results.

  1. First posted

    Jul 14, 2009

  2. Study start

    Jul 2009

  3. Primary completion

    Sep 2010

  4. Study completion

    Sep 2010

  5. Results posted

    Jan 30, 2013

  6. Registry updated

    Nov 5, 2013

Outcomes

What the study measures.

Primary outcomes

Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be a 9 out of 12 week APC responder if, for at least 9 out of the first 12 weeks of the treatment period, the patient had at least 3 CSBMs, had an increase of at least 1 CSBM from baseline, and had a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week. The AP score assesses patient's worst AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. SBM is defined as a bowel movement that occurs in the absence of laxative, enema, or suppository use on either the calendar day of the bowel movement or the calendar day before the bowel movement. CSBM is defined as an SBM associated with a sense of complete evacuation.

Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be a CSBM 3+1 responder if, for at least 9 out of the 12 weeks of the treatment period, the patient had at least 3 CSBMs and experienced an increase of at least 1 CSBM from baseline during a particular week. A CSBM was defined as a Spontaneous Bowel Movement (SBM) that was associated with a sense of complete evacuation. An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.

Abdominal Pain Responder, 9 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be an abdominal pain responder if, for at least 9 out of the 12 weeks of the treatment period, they experienced a decrease of at least 30 percent in the mean abdominal pain score from baseline during a particular week. The Abdominal Pain score assesses patient's worst abdominal pain in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be a 6 out of 12 week APC responder if, for at least 6 out of the first 12 weeks of the treatment period, the patient had an increase of at least 1 CSBM from baseline, and had a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week. The AP score assesses patient's worst AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP. SBM is defined as a bowel movement that occurs in the absence of laxative, enema, or suppository use on either the calendar day of the bowel movement or the calendar day before the bowel movement. CSBM is defined as an SBM associated with a sense of complete evacuation.

Secondary outcomes

12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency

Time frame · Change from Baseline to Week 12

The change from baseline in 12-week CSBM frequency (i.e., weekly CSBM frequency over the first 12 weeks of the Treatment Period).

12-Week Spontaneous Bowl Movement (SBM) Frequency

Time frame · Change from Baseline to Week 12

The change from baseline in 12-week SBM frequency (i.e., weekly SBM frequency over the first 12 weeks of the Treatment Period).

12-Week Change in Stool Consistency

Time frame · Change from Baseline to Week 12

The consistency of each BM was assessed by patients using the 7-point Bristol Stool Form Scale (BSFS) from 1 to 7. 1. = separate hard lumps like nuts \[difficult to pass\] 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges \[passed easily\] 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces \[entirely liquid\]).

12-Week Change in Severity of Straining

Time frame · Change from Baseline to Week 12

Straining is measured on a 5-point scale where a value of 1 is "not at all" and a value of 5 is "an extreme amount".

12-Week Change in Abdominal Pain Score

Time frame · Change from Baseline to Week 12

Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

12-Week Change in Abdominal Discomfort

Time frame · Change from Baseline to Week 12

Abdominal discomfort was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".

12-Week Change in Bloating

Time frame · Change from Baseline to Week 12

Bloating was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".

Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment

Time frame · Change from Baseline to Week 12

A patient is considered to be a CSBM responder if, for at least 6 out of the 12 weeks of the treatment period, an increase of at least 1 CSBM per week from baseline was experienced.

Abdominal Pain Responder for 6 Out of 12 Weeks

Time frame · Change from Baseline to Week 12

A patient is considered to be an AP responder if, for at least 6 out of the first 12 weeks of the treatment period, the patient had a decrease of at least 30 percent in their Abdominal Pain score from baseline during a particular week.

12-Week Percent of Abdominal Pain-free Days

Time frame · Change from Baseline to Week 12

Abdominal pain free (APF) days are those days where the patient reported a score of '0' for abdominal pain at its worst. Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings * Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests * Patient meets protocol criteria for diagnosis of IBS-C * Patient demonstrates continued IBS-C through Pretreatment Period * Patient is compliant with IVRS Exclusion Criteria: * Patient has history of loose or watery stools * Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain * Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

Study locations

107 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Ironwood Investigational Site

Birmingham, Alabama, United States

Ironwood Investigational Site

Huntsville, Alabama, United States

Ironwood Investigational Site

Phoenix, Arizona, United States

Ironwood Investigational Site

Tempe, Arizona, United States

Ironwood Investigational Site

Tucson, Arizona, United States

Ironwood Investigational Site

Tucson, Arizona, United States

Ironwood Investigational Site

Sherwood, Arkansas, United States

Ironwood Investigational Site

Anaheim, California, United States

Ironwood Investigational Site

Chula Vista, California, United States

Ironwood Investigational Site

Encinitas, California, United States

Ironwood Investigational Site

Garden Grove, California, United States

Ironwood Investigational Site

Laguna Hills, California, United States

Ironwood Investigational Site

Orange, California, United States

Ironwood Investigational Site

San Carlos, California, United States

Ironwood Investigational Site

San Diego, California, United States

Ironwood Investigational Site

San Diego, California, United States

Ironwood Investigational Site

San Diego, California, United States

Ironwood Investigational Site

Colorado Springs, Colorado, United States

Ironwood Investigational Site

Bristol, Connecticut, United States

Ironwood Investigational Site

Boynton Beach, Florida, United States

Ironwood Investigational Site

Hollywood, Florida, United States

Ironwood Investigational Site

Inverness, Florida, United States

Ironwood Investigational Site

Jacksonville, Florida, United States

Ironwood Investigational Site

Jacksonville, Florida, United States

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.